X
InnoPharmax
About
About Us
Organization
Our History
News
News
R&D
Pipeline
Anti-infection Agents
Contrast Agents
Oncology Agents
Immunological Agents
Drugs for Rare Diseases
Active Pharmaceutical Ingredient
Products
GemOral
N11005
Technologies
OralPAS®
OralPAS Pro®
MUCR™
Investors
Financial Information
Company Profile
Monthly Revenue
Financial Statements
Corporate Governance
Board Meeting
Committee
Internal Audit
Rule of Procedure
Corporate Social Responsibility
Shareholders Services
Annual Reports
Shareholders' Meetings
Announcements
Contact
Contacts
Contact Information
Career Opportunities
ZH-TW
News
InnoPharmax have signed supplementary agreement with Shandong New Times Pharmaceuticals for Sapropterin Dihydrochloride.
2022/08/29
Patent of “Oral Administration of Unstable or Poorly-Absorbed Drugs (N11005)” was granted in U.S.
2022/03/29
First-Patient-In (FPI) of N11005-Oral Insulin Investigator-Initiated-Trial (IIT).
2022/02/10
InnoPharmax have entered supply contract with Astellas in Germany for the Bendamustine.
2022/01/18
InnoPharmax is invited to participate in the online corporate presentation held by Yuan Fu Securities..
2021/12/23
More
uGear Design
-
Website Info.